[Comment] Decentralised, point-of-care CAR-T for multiple myeloma

BCMA chimeric antigen receptor (CAR) T-cell therapy represents a major breakthrough in the treatment of multiple myeloma.1 Idecabtagene vicleucel and ciltacabtagene autoleucel are so far the only two industrial BCMA CAR T-cell therapies that have received regulatory approval.2,3 Both have shown unprecedented clinical efficacy, translating into progression-free survival that largely exceeds the expected 3–4-month progression-free survival in relapsed or refractory multiple myeloma.2–4 In The Lancet Oncology, Aina Oliver-Caldés and colleagues5 report the results of ARI0002h, a BCMA CAR T-cell therapy developed in Spain by an academic group, in 30 patients with relapsed or refractory multiple myeloma.